Baxalta Inc.

Pharmaceuticals
United States
Earnings Per Share Growth (%)N/A
Cost of Goods Sold (US$ Millions)$2,386
Current Liabilities (US$ Millions)$1,911
Total Assets (US$ Millions)$4,708
Long Term Debt$5,265
Return on Equity16.63%
Revenue (US$ Millions)$6,148
Total Company Assets$12,329
Revenue Growth (%)3.29%
Net Income (US$ Millions)$956
Earnings Per Share (US$)N/A
Total Equity (US$ Millions)$3,924
Profit Margin (%)15.55%
Debt To Equity Ratio (%)1.34%
Inventory Turnover$2,173